Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
13.28
+1.13 (9.30%)
Dec 30, 2024, 4:00 PM EST - Market closed
Atara Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 100.44 | 8.57 | 63.57 | 20.34 | - | - | Upgrade
|
| Revenue Growth (YoY) | 2111.34% | -86.51% | 212.55% | - | - | - | Upgrade
|
| Cost of Revenue | 180.37 | 228.05 | 269.99 | 282 | 244.65 | - | Upgrade
|
| Gross Profit | -79.93 | -219.48 | -206.42 | -261.66 | -244.65 | - | Upgrade
|
| Selling, General & Admin | 39.48 | 49.8 | 68.13 | 78.8 | 64.4 | 79.58 | Upgrade
|
| Research & Development | - | - | - | - | - | 216.1 | Upgrade
|
| Operating Expenses | 39.48 | 49.8 | 68.13 | 78.8 | 64.4 | 295.68 | Upgrade
|
| Operating Income | -119.41 | -269.28 | -274.55 | -340.46 | -309.05 | -295.68 | Upgrade
|
| Interest Expense | -4.77 | -5.29 | -0.37 | - | - | - | Upgrade
|
| Interest & Investment Income | 2.22 | 5.43 | 3.06 | 2.14 | 3.28 | 3.39 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.61 | -0.25 | -0.7 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -121.35 | -269.38 | -272.56 | -338.33 | -305.78 | -292.29 | Upgrade
|
| Merger & Restructuring Charges | -11.79 | -6.73 | -5.96 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -1.77 | -0.83 | 1.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 50.24 | - | - | - | Upgrade
|
| Pretax Income | -133.14 | -276.11 | -228.29 | -340.1 | -306.61 | -290.96 | Upgrade
|
| Income Tax Expense | 0.02 | 0.02 | 0.01 | 0.05 | 0.02 | 0.01 | Upgrade
|
| Net Income | -133.16 | -276.13 | -228.3 | -340.14 | -306.62 | -290.98 | Upgrade
|
| Net Income to Common | -133.16 | -276.13 | -228.3 | -340.14 | -306.62 | -290.98 | Upgrade
|
| Shares Outstanding (Basic) | 6 | 4 | 4 | 4 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 6 | 4 | 4 | 4 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 40.71% | 3.85% | 8.88% | 26.63% | 44.17% | 17.11% | Upgrade
|
| EPS (Basic) | -22.60 | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | Upgrade
|
| EPS (Diluted) | -22.60 | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | Upgrade
|
| Free Cash Flow | -94.85 | -194.2 | -274.62 | -231.1 | -185.27 | -241.36 | Upgrade
|
| Free Cash Flow Per Share | -16.10 | -45.84 | -67.32 | -61.68 | -62.61 | -117.60 | Upgrade
|
| Operating Margin | -118.88% | -3140.98% | -431.86% | -1673.85% | - | - | Upgrade
|
| Profit Margin | -132.58% | -3220.88% | -359.12% | -1672.28% | - | - | Upgrade
|
| Free Cash Flow Margin | -94.44% | -2265.25% | -431.98% | -1136.19% | - | - | Upgrade
|
| EBITDA | -114.25 | -264.45 | -268.9 | -331.12 | -300.72 | -288.54 | Upgrade
|
| D&A For EBITDA | 5.16 | 4.83 | 5.65 | 9.35 | 8.33 | 7.14 | Upgrade
|
| EBIT | -119.41 | -269.28 | -274.55 | -340.46 | -309.05 | -295.68 | Upgrade
|
| Revenue as Reported | 100.44 | 8.57 | 63.57 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.